News und Analysen

Share prices of Advanced Micro Devices (NASDAQ: AMD) soared to new highs recently on news of a transformative deal to supply chips for ChatGPT maker OpenAI. The surge in the share price comes ahead

The S&P 500 index was recently offering a tiny dividend yield of 1.2%. You can get as much as 7% from some of the world's largest drugmakers. But sometimes, a high yield is a sign of risk.

What does

One struggling pharma stock that could use a boost from a strong earnings report is Pfizer (NYSE: PFE). The company's valuation has plummeted in recent years as patent cliffs and question marks

If you are looking for a healthcare stock to add to your portfolio as October draws to a close, consider Intuitive Surgical (NASDAQ: ISRG), Merck (NYSE: MRK), and Johnson & Johnson (NYSE: JNJ). Each

Nvidia (NASDAQ: NVDA) is transforming from a graphics processing unit (GPU) champion to an artificial intelligence (AI) infrastructure cash engine. Learn about Blackwell, DGX Spark, and DGX Cloud

Being a big company comes with a lot of positives. But there are negatives, too. Some businesses end up imploding under their own weight because they face increased scrutiny and competition and

What if you had invested in any of the current leaders in the biotech industry before they established themselves as such? You'd have earned terrific returns. While we can't go back in time to do

Vertex Pharmaceuticals (NASDAQ: VRTX) and Pfizer (NYSE: PFE) are both among the largest drugmakers in the world. The latter currently has the edge in this department, with a market cap of $141

A big dividend yield is nice to see, but it shouldn't be the only thing you look at when buying a stock. The actual business behind the yield is, in fact, more important. That's why you'll need to

On Friday, Pennsylvania-based Conestoga Capital Advisors disclosed selling 855,435 shares of Vertex (NASDAQ:VERX), an estimated $24.8 million transaction based on average prices in the third

There's been some choppy activity in the stock market in October as the intensifying trade war between the U.S. and China has rattled investors. But the outlook for growth in the technology sector

Dividend investors shouldn't be dissuaded from investing just because the S&P 500 (SNPINDEX: ^GSPC) has a miserly 1.2% yield. If you dig in a bit, you can find attractive dividend stocks, including

Investors looking for stocks that can produce eye-popping gains in a short time frame often turn toward biotechnology stocks. In this wonky industry, encouraging results from a clinical trial can

It isn't all that difficult to find high-yield dividend stocks -- say, those paying out at more than 4%. The real trick is finding a company that produces sufficient profitability and free cash flow

Explore the exciting world of Summit Therapeutics (NASDAQ: SMMT) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights

Dividend stocks are arguably worth a premium in the current environment. Between a prolonged government shutdown and President Donald Trump's trade wars, the economy and the market might be heading

It's no surprise that tech shares are among the best that you can own in the stock market. These are companies that are on the cutting edge of innovation, bringing about changes that will have

When investors talk about artificial intelligence (AI) chips, they often mention Nvidia (NASDAQ: NVDA). It's the world's largest producer of discrete GPUs for data centers, where they're used to

In common with many other small-cap biotech stocks, Viking Therapeutics' (NASDAQ: VKTX) share price tends to be volatile as investors react to the ebb and flow of news from the company. Today was an

Image source: Getty Images

LOS ANGELES CAPITAL MANAGEMENT LLC increased its position in AbbVie by 304,281 shares during Q3 2025, an estimated $61.96 million trade based on the average price for Q3

Verity & Verity, LLC disclosed in its Oct. 21, 2025, SEC filing a purchase of 907,855 shares of Pfizer Inc. valued at an estimated $22.41 million for the quarter ended Sep. 30, 2025.

According to a

AT&T (NYSE: T) is the third-largest wireless carrier in the U.S., serving over 90 million customers. Wireless generates the majority of the company's roughly $120 billion in annual revenue. AT&T

Explore the exciting world of AbbVie (NYSE: ABBV) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends